Cardiac Biomarkers — The Laboratory's Role in Heart Attack Diagnosis and Cardiac Risk Assessment

The Laboratory at the Heart of the Matter: Understanding Cardiac Biomarkers

Every 33 seconds, someone in the world dies from cardiovascular disease.

It is the world's biggest killer — responsible for more deaths annually than all cancers combined. In Ghana, as in much of sub-Saharan Africa, the burden is rising sharply. Once considered a disease of affluence, cardiovascular disease now cuts across every socioeconomic stratum, driven by urbanization, dietary shifts, and the same epidemic of hypertension and diabetes that is reshaping public health across the continent.

Acute myocardial infarction (AMI) — the heart attack — is one of the most time-critical emergencies in medicine. Here, the principle "time is muscle" reigns supreme. Every minute of myocardial ischaemia without reperfusion means more cardiomyocytes die. The faster the diagnosis is made and treatment initiated, the better the outcome. Delays measured in minutes translate to permanent loss of heart function.

At the centre of modern cardiac diagnosis is the clinical laboratory. Cardiac biomarkers — proteins released from damaged heart muscle into the blood — give clinicians objective, measurable evidence of myocardial injury within hours of onset. These numbers don't just confirm what the ECG suggests; they guide decisions about thrombolysis, angiography, and long-term management.

In this exploration, we'll walk through the science behind cardiac biomarkers, the tests that measure them, and how they are used in clinical practice — because understanding what these numbers mean is essential for every healthcare professional and every patient.

1. The Pathophysiology of Myocardial Infarction: What Happens in a Heart Attack

To understand cardiac biomarkers, we must first understand what happens when a heart attacks.

The process begins with atherosclerosis — the gradual buildup of fatty plaques in the coronary arteries. For years, these plaques may cause no symptoms. But some plaques are vulnerable — thin-capped, inflamed, and prone to rupture.

When such a plaque ruptures, it triggers a cascade:

Platelets aggregate at the site of rupture
A thrombus (clot) forms
The vessel becomes partially or completely occluded

Downstream myocardium — the heart muscle supplied by that vessel — becomes ischaemic. Within minutes, cells begin to suffer. Within 20 to 40 minutes, if blood flow is not restored, irreversible cell death (necrosis) begins.

As cardiomyocytes die, their cell membranes rupture. Intracellular contents — including structural proteins, enzymes, and regulatory molecules — spill into the interstitial space and eventually into the bloodstream. These released proteins are the cardiac biomarkers we measure.

Types of Myocardial Infarction Based on ECG:

Type	ECG Finding	Mechanism	Treatment
STEMI (ST-Elevation MI)	ST elevation	Complete vessel occlusion	Emergency reperfusion (PCI or thrombolysis)
NSTEMI (Non-ST-Elevation MI)	No ST elevation	Partial occlusion; subendocardial ischaemia	Urgent angiography; medical management
Unstable Angina	No ST elevation; no biomarker elevation	Ischaemia without necrosis	Medical stabilization; risk stratification

The distinction matters because STEMI requires immediate reperfusion — every 30-minute delay in opening the vessel increases mortality by 7–8%. The laboratory's role is to confirm the diagnosis and guide subsequent management.

2. Troponin — The Gold Standard

2.1 Biology of Cardiac Troponin

Troponin is part of the regulatory complex that controls striated muscle contraction. It is the switch that turns muscle contraction on and off. The complex consists of three subunits:

Troponin T (TnT) — binds to tropomyosin, positioning the complex on the thin filament
Troponin I (TnI) — inhibits actin-myosin interaction; the "brake" on contraction
Troponin C (TnC) — binds calcium; the trigger for contraction

The cardiac isoforms — cardiac troponin T (cTnT) and cardiac troponin I (cTnI) — are encoded by different genes than their skeletal muscle counterparts. This genetic distinction gives them extraordinary specificity for the heart. Under normal circumstances, these proteins are not present in the blood in significant quantities. They are locked inside cardiomyocytes, doing their work.

When cardiomyocytes are injured, troponin is released in two phases:

A small cytosolic pool is released almost immediately when cell membranes become leaky
A larger pool from structural disintegration of myofibrils is released as cells die

cTnT and cTnI appear in the blood 3–6 hours after AMI onset , peak at 12–24 hours , and remain elevated for 7–14 days . This wide diagnostic window is clinically valuable — it allows detection of myocardial injury even if the patient presents days after the event.

2.2 High-Sensitivity Cardiac Troponin (hs-cTn): A Revolution in Diagnosis

Modern high-sensitivity troponin (hs-cTnT, hs-cTnI) assays can detect troponin at concentrations 10–100 times lower than conventional assays. This is not a minor improvement — it is a paradigm shift.

What hs-cTn enables:

Detection of very small amounts of myocardial injury — microinfarcts that would have been missed with older assays
Earlier diagnosis — the 0h/1h or 0h/2h rapid rule-in/rule-out algorithms can diagnose or exclude AMI within 1–2 hours of presentation
Improved sensitivity for NSTEMI — many patients with NSTEMI had "negative" troponin with older assays; hs-cTn captures them

The 99th percentile upper reference limit (URL) — the upper limit of normal in a healthy reference population — is the key decision threshold. Values above the 99th percentile, with a rising and/or falling pattern (kinetic change), confirm acute myocardial injury.

But here is the critical nuance: elevated hs-cTn is NOT specific to AMI.

It also rises in:

Pulmonary embolism — increased right ventricular strain
Heart failure — myocyte stretch and necrosis
Myocarditis — inflammatory myocardial injury
Type 2 MI — demand ischaemia in sepsis, arrhythmia, severe anaemia
Renal failure — reduced clearance; chronic troponin elevation common
Rhabdomyolysis — severe muscle injury (though cTnI is more cardiac-specific than cTnT)
Cardiac contusion — trauma
Takotsubo cardiomyopathy (stress-induced cardiomyopathy)

This is why the pattern of rise and fall — the kinetics — and the clinical context are essential for interpretation. A single elevated troponin in a patient with renal failure and no chest pain is not diagnostic of AMI. The same value in a patient with crushing chest pain and dynamic ECG changes tells a different story.

The 0h/1h Algorithm:

The European Society of Cardiology recommends a rapid algorithm using hs-cTn:

Rule-out: Very low baseline troponin (<5 ng/L for hs-cTnT) AND no significant rise at 1 hour → AMI effectively excluded
Rule-in: Baseline troponin significantly elevated (>52 ng/L for hs-cTnT) OR large rise at 1 hour → AMI confirmed; proceed to angiography
Observation zone: Intermediate values require further testing (3-hour repeat)

This algorithm has reduced emergency department length of stay and enabled earlier discharge for low-risk patients.

3. Other Cardiac Biomarkers: Their Roles and Limitations

3.1 Creatine Kinase (CK) and CK-MB

CK is an enzyme found in muscle, brain, and heart. It exists in three isoforms:

CK-MM — predominantly in skeletal muscle
CK-MB — enriched in cardiac muscle (about 20–30% of total CK in heart)
CK-BB — predominantly in brain

CK-MB rises 4–6 hours after MI , peaks at 18–24 hours , and returns to normal within 48–72 hours — a shorter window than troponin. This makes it useful for detecting reinfarction. If a patient has a confirmed MI and CK-MB normalizes, then rises again, that suggests new myocardial injury.

CK-MB has largely been replaced by hs-cTn for initial MI diagnosis due to:

Lower cardiac specificity (CK-MB is also present in skeletal muscle, though in smaller amounts)
Shorter diagnostic window (misses late presentations)
Lower sensitivity for small infarcts

However, CK-MB remains clinically useful in:

The post-MI period for detecting reinfarction
Resource-limited settings where hs-cTn assays are not available
Perioperative MI detection after cardiac surgery

3.2 Myoglobin: The Early Marker

Myoglobin is a small oxygen-carrying protein found in all muscle tissue. It rises very early after MI (1–3 hours) , peaks quickly, and returns to normal within 24 hours.

Advantage: Excellent negative predictive value in the first 2 hours. A normal myoglobin at presentation makes AMI very unlikely.

Disadvantage: No cardiac specificity. Elevated in any muscle injury — falls, intramuscular injections, strenuous exercise, rhabdomyolysis.

Myoglobin has been largely supplanted by hs-cTn , which offers both early sensitivity and cardiac specificity. It is rarely used in modern practice except in settings without hs-cTn access.

3.3 B-type Natriuretic Peptide (BNP) and NT-proBNP: The Heart Failure Markers

BNP and its inactive precursor fragment NT-proBNP are neurohormones secreted by the ventricles in response to increased wall stress — volume overload, pressure overload, or both. They are the primary laboratory biomarkers for heart failure (HF) diagnosis and monitoring.

Key clinical uses:

Diagnosis: Elevated BNP/NT-proBNP confirms heart failure in patients presenting with breathlessness. Excellent negative predictive value — normal levels virtually exclude HF as the cause of dyspnoea.
Prognosis: Higher levels correlate with worse outcomes; falling levels suggest treatment response.
Monitoring: Used to guide diuretic therapy and assess adequacy of decongestion.

What causes elevation:

Heart failure (systolic or diastolic)
Pulmonary embolism (right heart strain)
Atrial fibrillation
Renal failure (reduced clearance)
Sepsis (inflammatory)
Advanced age (BNP/NT-proBNP rise with age)

What causes normal levels in HF:

Obesity — adipocytes express natriuretic peptide clearance receptors, leading to lower circulating levels
Non-cardiac causes of dyspnoea — COPD exacerbation, pneumonia

Interpretation cutoffs (ESC guidelines for acute HF diagnosis):

Age	NT-proBNP Cutoff
<50 years	>450 pg/mL
50–75 years	>900 pg/mL
>75 years	>1800 pg/mL

For BNP, the typical cutoff is >100 pg/mL , though lower cutoffs (35 pg/mL) are used for chronic HF.

Pre-analytical considerations:

BNP is unstable — must be collected in EDTA, processed quickly, and kept cold. Degrades rapidly at room temperature.
NT-proBNP is more stable — EDTA or serum acceptable; less affected by sample handling.

3.4 D-Dimer in Chest Pain: The PE Rule-Out

While not a cardiac marker per se, D-dimer is frequently measured in patients presenting with chest pain and suspected pulmonary embolism (PE) .

D-dimer is a fibrin degradation product — it reflects active clot formation and breakdown. A negative D-dimer in a patient with low or intermediate pre-test probability effectively excludes PE , avoiding the need for CT pulmonary angiography.

But D-dimer has limitations:

Elevated in many conditions: Surgery, trauma, pregnancy, malignancy, infection, inflammation
False positives are common in hospitalized patients, especially the elderly
Poor specificity — a positive D-dimer does not confirm PE; it only indicates imaging is needed

D-dimer is most valuable as a rule-out test , not a rule-in test.

4. Cardiac Risk Assessment Markers: Predicting Disease Before It Strikes

4.1 Lipid Profile: The Foundation of Risk Assessment

Fasting lipid profiles — total cholesterol, LDL-C, HDL-C, and triglycerides — are fundamental to cardiovascular risk assessment. These are not diagnostic of acute events, but they are essential for primary and secondary prevention.

LDL-C (low-density lipoprotein cholesterol) : The "bad" cholesterol. The primary therapeutic target. Every 1 mmol/L reduction in LDL-C reduces major cardiovascular events by approximately 22%.
HDL-C (high-density lipoprotein cholesterol) : The "good" cholesterol. Higher levels are protective.
Triglycerides: Elevated levels are associated with increased risk, particularly when combined with low HDL.
Non-HDL-C (total cholesterol minus HDL): Increasingly recommended as it captures all atherogenic lipoproteins (VLDL, IDL, LDL, Lp(a)).

Fasting requirements: Traditional guidelines require 9–12 hours fasting for triglycerides and LDL-C calculation via the Friedewald equation. However, non-HDL-C and direct LDL-C measurement are valid in non-fasting samples , and many guidelines now permit non-fasting lipid testing for most patients.

4.2 Lipoprotein(a) [Lp(a)]: The Genetic Risk Factor

Lp(a) is a genetically determined LDL-like particle with an additional apolipoprotein(a) protein attached. It is an independent, causal risk factor for:

Atherosclerotic cardiovascular disease (ASCVD)
Calcific aortic valve disease
Ischaemic stroke

Key facts:

Genetically determined — levels are largely fixed from birth and not significantly modifiable by diet, exercise, or standard lipid-lowering drugs
Measured once in a lifetime — repeat testing is unnecessary
Levels >50 mg/dL (>125 nmol/L) are considered high risk
Ethnic variation: Levels are higher in people of African descent; the risk threshold may be lower in these populations

Why it matters: Emerging RNA-targeted therapies (including inclisiran and pelacarsen) can specifically lower Lp(a). Knowing a patient's Lp(a) level identifies those who may benefit from these therapies when they become available.

4.3 hsCRP (High-Sensitivity C-Reactive Protein): The Inflammation Marker

CRP is an acute-phase protein produced by the liver in response to inflammation. At high-sensitivity levels , hsCRP predicts cardiovascular risk independently of lipids.

Low risk: hsCRP <1 mg/L
Moderate risk: hsCRP 1–3 mg/L
High risk: hsCRP >3 mg/L

The JUPITER trial demonstrated that individuals with normal LDL-C but elevated hsCRP (>2 mg/L) had significant cardiovascular risk reduction with statin therapy. This established hsCRP as a tool for identifying patients who benefit from primary prevention despite normal cholesterol levels.

Caveat: hsCRP is non-specific — elevated in any inflammatory condition (infection, autoimmune disease, trauma). It should be measured when the patient is clinically stable.

5. Pre-Analytical and Analytical Considerations: Getting It Right

The best biomarker is useless if the sample is mishandled.

Test	Collection	Critical Considerations
Troponin	EDTA or heparin plasma	Haemolysis causes false-positive results. Do not use haemolysed samples.
BNP	EDTA plasma	Process immediately; BNP degrades rapidly at room temperature. Keep cold.
NT-proBNP	EDTA or serum	More stable than BNP; less affected by handling.
Lipids	Serum (fasting preferred)	Non-fasting acceptable for non-HDL-C and direct LDL-C.
Serial sampling	0h and 1h (or 0h and 3h)	The kinetic pattern is diagnostic. Single samples are insufficient.

The troponin kinetic pattern:

Acute MI: Rapid rise (usually >20–50% change in 1–3 hours) followed by gradual fall
Chronic elevation (renal failure, heart failure): Stable, with minimal change over time
Type 2 MI: Rise with demand ischaemia, fall as underlying condition resolves

Without serial sampling, the laboratory cannot distinguish acute from chronic injury.

Conclusion: The Laboratory at the Centre of Cardiac Care

The laboratory is not just a support service in cardiac care — it is the engine of diagnosis. Without accurate, rapid troponin results, cardiologists cannot confidently diagnose AMI. Without BNP/NT-proBNP, heart failure management loses its objective anchor. Without lipid profiles and hsCRP, primary prevention is a shot in the dark.

In Ghana and across West Africa, where cardiovascular disease is rising and resources are often limited, the role of the laboratory is even more critical. Every troponin result that arrives in the emergency department influences whether a patient receives thrombolysis, is transferred for angiography, or is discharged home. Every BNP result shapes the management of breathlessness. Every lipid profile guides years of preventive therapy.

As medical laboratory scientists — and as patients seeking to understand our own health — understanding the science behind cardiac biomarkers — their biology, kinetics, clinical significance, and analytical limitations — makes us true partners in the fight against the world's biggest killer.

Your Heart. Your Numbers. Your Understanding.

Whether you're managing a chronic condition, recovering from a cardiac event, or simply trying to understand your risk, knowing what your cardiac test results mean is essential.

Visit our free interpretation tool at:
https://VincentAkwas.github.io/lablens

Get instant, detailed explanations for your troponin, BNP/NT-proBNP, lipid profile, hsCRP, and all your laboratory results — with clinical commentary that helps you understand what your numbers mean and what questions to ask next.

Because when it comes to the heart, knowledge is not just power. It is survival.

Search This Blog

LabLens MLS Hub